Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDF Cardiff Oncology, Inc.

Trading 02-25 09:36:32 EST

1.84

+0.14

+7.94%

High1.86	Low1.74	Vol131.40K
Open1.75	D1 Closing1.70	Amplitude7.06%
Mkt Cap123.61M	Tradable Cap120.62M	Total Shares67.36M
T/O236.25K	T/O Rate0.20%	Tradable Shares65.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":1.835,"timestamp":1772030190558,"preClose":1.7,"halted":0,"volume":131401,"delay":0,"changeRate":0.07941176470588236,"floatShares":65730400,"shares":67360564,"eps":-0.793959,"marketStatus":"Trading","change":0.135,"latestTime":"02-25 09:36:32 EST","open":1.75,"high":1.86,"low":1.74,"amount":236253.479158,"amplitude":0.070588,"askPrice":1.84,"askSize":1335,"bidPrice":1.82,"bidSize":1250,"shortable":3,"etf":0,"ttmEps":-0.793959,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":1.77,"preClose":1.7,"latestTime":"09:28 EST","volume":3502,"amount":6276.2574346,"timestamp":1772029723715,"change":0.07,"changeRate":0.041176,"amplitude":0.033294},"postHourTrading":{"tag":"盘后","latestPrice":1.7801,"preClose":1.7,"latestTime":"19:57 EST","volume":57161,"amount":102345.9292,"timestamp":1771981068157,"change":0.0801,"changeRate":0.047118,"amplitude":0.117647},"volumeRatio":12.120103,"impliedVol":1.1354,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/CRDF/tweets","defaultTab":"tweets","newsList":[{"id":"2614779291","title":"Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF) and Alphatec Holdings (ATEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614779291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614779291?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:50","pubTimestamp":1771991409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiff Oncology (CRDF – Research Report) and Alphat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cardiff-oncology-crdf-and-alphatec-holdings-atec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cardiff-oncology-crdf-and-alphatec-holdings-atec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XBI","LU0566484027.USD","BK4082","XLV","ATEC","HCSG","LU1559883803.SGD","BK4139","LU0128526141.USD","BK4588","BK4581","BK4585","LABU","CRDF","BK4137"],"gpt_icon":0},{"id":"2614572345","title":"Press Release: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614572345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614572345?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:30","pubTimestamp":1771968600,"startTime":"0","endTime":"0","summary":"Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:. Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026. Continued Dr. Mohindru, \"Based on these results, we plan to advance the 30 mg dose of onvansertib with FOLFIRI/bev into our proposed registrational program and expect to provide detailed data and registrational plans after discussions with the FDA in the first half of 2026. As we transition into late-stage clinical development and continue to strengthen our leadership and operational teams, we remain focused on disciplined execution, progressing our lead program toward a potential new standard of care in first-line RAS-mutated mCRC.\". randomized Phase 2 trial evaluating onvansertib in combination with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2613758179","title":"Cardiff Oncology Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758179","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758179?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884008,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc  expected to post a loss of19cents a share - Earnings Preview Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to  show a fall in quarterly revenue when it reports  results on Febr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ2DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2612044104","title":"Cardiff Oncology to Present at Oppenheimer Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612044104","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612044104?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502434,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4n9Qy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","NDAQ","BK4588","CRDF","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2610665477","title":"Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Brigitte Lindsay","url":"https://stock-news.laohu8.com/highlight/detail?id=2610665477","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610665477?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:00","pubTimestamp":1770670840,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Brigitte Ute Lindsay as the beneficial owner, serving in the role of Chief Accounting Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4DPqQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Brigitte Lindsay","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2607749872","title":"Cardiff Oncology Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2607749872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607749872?lang=en_us&edition=fundamental","pubTime":"2026-01-29 01:27","pubTimestamp":1769621220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRDF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 12:27 ET (17:27 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2606053718","title":"Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2606053718","media":"Benzinga_recent_news","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606053718?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:23","pubTimestamp":1769599380,"startTime":"0","endTime":"0","summary":"Cardiff Oncology shares fell 32% after a sudden CEO and CFO exit, trial strategy changes, and a negative analyst update that cut success odds and market potential.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/28/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/28/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2606577718","title":"Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2606577718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606577718?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:15","pubTimestamp":1769598948,"startTime":"0","endTime":"0","summary":"H.C. Wainwright says the selloff yesterday in shares of Cardiff Oncology (CRDF) brings an attractive entry point. The firm finds updated CRDF-004 t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-selloff-brings-attractive-entry-point-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-selloff-brings-attractive-entry-point-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606392377","title":"Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2606392377","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606392377?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:11","pubTimestamp":1769533869,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on January 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL8gjfpN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","CRDF","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4585","SG9999014021.USD"],"gpt_icon":0},{"id":"2606787004","title":"BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787004?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:06","pubTimestamp":1769522791,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA HealthcareEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL6N3YS0NO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRO","BK4528","MOH","HL","LU1261432733.SGD","BA","UPS","PG","NEM","DDOG","UNHG","HCA","NET","LXEO","IE00BGHQF417.EUR","RTX","UNH","NEE","PUMP","IE00B1BXHZ80.USD","ELV","MUD","CDE","LU0267386448.USD","GLW","LU0225283273.USD","MUU","LU2317271919.USD","UNHW","CRM","PINS","EFC","AFRM","KMB","CRDF","LU0654597011.USD","CVS","MU","GM","MULL","LU1064131342.USD","LU0786609619.USD","NTLA","JBLU","NOC","AAL","HUM","AU"],"gpt_icon":0},{"id":"2606784417","title":"BUZZ-Cardiff Oncology plunges after top executives step down","url":"https://stock-news.laohu8.com/highlight/detail?id=2606784417","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606784417?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:02","pubTimestamp":1769518946,"startTime":"0","endTime":"0","summary":"BUZZ-Cardiff Oncology plunges after top executives step down** Shares of drug developer Cardiff Oncology CRDF.O fall 32% to $2 premarket** Cardiff's CEO and CFO both step down, effective immediately** Co says board member Mani Mohindru appointed as interim CEO while it searches for replacements** Separately, CRDF says a mid-stage trial showed that adding its experimental drug, onvansertib, to a standard firstline chemotherapy regimen improved response rates and delayed disease progression in patients with a hard-to-treat form of colorectal cancer** Says patients who received the higher 30-milligram dose of onvansertib alongside standard chemotherapy had a 72% response rate, compared with 43% for those on standard treatment alone** Adds that it plans to launch a larger, late-stage trial later this year ** In 2025, CRDF fell 34%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL4N3YS1DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-Cardiff Oncology plunges after top executives step down","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606890237","title":"Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down","url":"https://stock-news.laohu8.com/highlight/detail?id=2606890237","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606890237?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:16","pubTimestamp":1769516202,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (CRDF) announced a leadership transition. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-announces-ceo-erlander-cfo-levine-have-stepped-down-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-announces-ceo-erlander-cfo-levine-have-stepped-down-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606077789","title":"Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib","url":"https://stock-news.laohu8.com/highlight/detail?id=2606077789","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606077789?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:10","pubTimestamp":1769515844,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (CRDF) announced a “positive” update from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-announces-update-from-crdf-004-phase-2-trial-of-onvansertib-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-announces-update-from-crdf-004-phase-2-trial-of-onvansertib-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606789664","title":"Cardiff Oncology Inc: Data Support Selection of 30 Mg Onvansertib Dose for Registrational Program in First-Line Ras-Mutated Mcr","url":"https://stock-news.laohu8.com/highlight/detail?id=2606789664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606789664?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:05","pubTimestamp":1769515500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA3CCD9M:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606306789","title":"Cardiff Oncology Inc: Onvansertib Added to Folfiri/Bev First-Line Standard of Care Regimen Showed Dose-Dependent Improvement in Overall Response Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2606306789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606306789?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:05","pubTimestamp":1769515500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA3CCD9M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606786087","title":"Cardiff Oncology Inc - Mark Erlander and James Levine Step Down From CEO and CFO Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786087","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606786087?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:00","pubTimestamp":1769515203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA7KGSH3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2606786033","title":"Cardiff Oncology Announces Executive Leadership Changes as It Transitions to Late-Stage Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786033","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606786033?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:00","pubTimestamp":1769515203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA7KGSH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTMX","BK4139","CRDF"],"gpt_icon":0},{"id":"2606744786","title":"Cardiff Oncology Inc - Mani Mohindru Appointed Interim CEO of Cardiff Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2606744786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606744786?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:00","pubTimestamp":1769515203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA7KGSH3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTMX","CRDF"],"gpt_icon":0},{"id":"2590365993","title":"Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365993","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365993?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227909,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. has announced that clinical data from an investigator-sponsored trial of onvansertib in chronic myelomonocytic leukemia  will be presented in a poster session at the 67th American Society of Hematology  Annual Meeting. The presentation is scheduled for December 8, 2025. The abstract related to this trial is available on the ASH Annual Meeting website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3ccy8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","CRDF"],"gpt_icon":0},{"id":"2590365604","title":"Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365604?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA4PRFNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.0897},{"period":"1month","weight":-0.4138},{"period":"3month","weight":-0.2735},{"period":"6month","weight":-0.1827},{"period":"1year","weight":-0.6272},{"period":"ytd","weight":-0.395}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.428571,"avgChangeRate":0.274174},{"month":3,"riseRate":0.384615,"avgChangeRate":0.093514},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.07213},{"month":5,"riseRate":0.461538,"avgChangeRate":0.052242},{"month":6,"riseRate":0.384615,"avgChangeRate":0.287657},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.07931},{"month":8,"riseRate":0.571429,"avgChangeRate":0.100833},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction